Navigation Links
Breckenridge Pharmaceutical Signs Letter of Intent for Long Term Agreement With Orit Laboratories (West Caldwell, NJ)
Date:4/10/2008

BOCA RATON, Fla., April 10 /PRNewswire/ -- Breckenridge announced today that it has entered into an agreement with Orit Laboratories to market 2 separate generic ANDA products. The first project is currently filed and pending FDA approval. The companies plan to file an ANDA with the FDA for the second product in the 3rd Quarter of 2008. Upon approval by the FDA, both products will be supplied by Orit Laboratories, and will be marketed and distributed by Breckenridge Pharmaceutical, Inc., on an exclusive basis in the USA.

About Breckenridge:

Breckenridge Pharmaceutical is a privately held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of ValuBrand(TM) and Generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 100 products, including multiple ANDA's, in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions and Topical preparations. http://www.bpirx.com

About Orit Laboratories:

Orit Laboratories specializes in the development of specialty generic pharmaceutical prescription products. The company focuses on the development of solid, liquid, soft gelatin capsule, modified release, and orally disintegrating dosage formulations using proprietary Drug Delivery Platforms. Orit Laboratories operates an FDA registered cGMP facility in West Caldwell, New Jersey that is approximately 10,000 sq. ft. The company is capable of pilot scale production, and their analytical laboratory operates under cGMP & cGLP. Orit has capabilities of Regulatory filing with the US Food and Drug Administration (FDA).


'/>"/>
SOURCE Breckenridge Pharmaceutical
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Breckenridge Pharmaceutical Enters Agreement With Helm AG (Hamburg, Germany) to Develop Additional ANDA Project
2. Breckenridge Pharmaceutical Settles Paragraph IV Litigation and Receives FDA Approval for its Oxcarbazepine ANDA
3. Breckenridge Pharmaceutical Signs Long Term Agreement with Helm AG (Hamburg, Germany)
4. Access Pharmaceuticals to Present New Data on ProLindac(TM) at the AACR Annual Meeting 2008 Conference
5. ISTA Pharmaceuticals Announces Receipt of Subpoena Relating to Promotional Practices for XIBROM(TM)
6. China Sky One Medical, Inc. Closes Acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.
7. Aida Pharmaceuticals, Inc. Announces New Antibiotic Drug Under Development
8. KV Pharmaceutical Company Announces Proposed Settlement in Principle of Derivative Shareholder Litigation
9. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... , ... July 21, 2017 , ... ... assistance and financial planning services to communities in the greater Birmingham area, is ... provide resources to underprivileged young people in the region. , The Chris Hammond ...
(Date:7/21/2017)... ... July 21, 2017 , ... Bernard R. Bach, Jr., MD, orthopaedic surgeon ... American Orthopaedic Society of Sports Medicine (AOSSM) , received the 2017 Robert E. Leach ... in Toronto, Canada. This prestigious award is given annually to honor those who have ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how to regulate their ... Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To help with ... Monday, July 21st. , The kit uses colorful, engaging and educational illustrations and ...
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... into why concussion rates are on the rise, say researchers presenting their work ... in Toronto, Ontario, Canada. , “The combination of evaluating the patterns of change ...
(Date:7/20/2017)... ... 2017 , ... Coats Rose, P.C. , a business ... expansion to the Midwest with the establishment of the firm’s new Cincinnati office. ... of counsels, John Peck and Robert Bruns, will establish and anchor Coats Rose’s ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... JERUSALEM , July 11, 2017 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... U.S. Food and Drug Administration (FDA) has agreed to ... successfully completed Phase IIb trial of its oral insulin ... The Phase IIb trial met primary and secondary endpoints ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences Inc. ... to support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing ... a leading Chinese Internet services provider, and joined by ... multiple infectious disease product programs targeting antibiotic resistant infections ... Founded by Dr. Rodolphe Barrangou and ...
(Date:7/5/2017)... BOTHELL, Wash. , July 5, 2017   ... a leading developer, manufacturer and marketer of proprietary clinical ... cryopreservation freeze media ("BioLife"), today announced that ... ("WAVI") its debt holder and largest shareholder, to modify ... Pursuant to the modification, WAVI agreed to ...
Breaking Medicine Technology: